Loading stock data…
BioAge Labs, Inc. (BIOA)
$24.95+1.19 (+5.01%)
Market ClosedLast close Jun 29
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioAge Labs, Inc. in the Healthcare sector is trading at $24.95 with a market capitalization of $713M. Wall Street consensus targets $49.50 (8 analysts), implying a +98.4% move over the next 12 months. The stock is currently near its 52-week high of $25.80, remaining 71.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +98.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.77M↓ | $3.08M↑ | $2.05M↓ | $2.41M↑ | $1.45M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$25.38M↑ | -$28.42M↓ | -$23.14M↑ | -$24.77M↓ | -$16.45M |
| Net Income | -$22.25M↑ | -$25.94M↓ | -$20.17M↑ | -$21.56M↓ | -$12.93M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$713.02M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.72%
Volume
Today's trading volume
768,425
Recent News
BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor
BioAge Labs has dosed the first participant in QUELL-CV, a 12-week, 160-patient Phase 2 proof-of-concept trial of its oral NLRP3 inhibitor BGE-102 in adults with obesity, elevated inflammation, and additional cardiovascular risk factors. An interesting angle is that BGE-102 emerged from BioAge’s human aging data platform, linking lower NLRP3 activity with greater longevity and positioning the drug at the intersection of cardiovascular and aging biology. We’ll now examine how this Phase 2...
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema. The company’s chief business officer
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage?
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best small cap pharma stocks to buy right now. TheFly reported on May 13 that BIOA received newly initiated coverage with a Buy rating and a $40 price target by […]
This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keefe, Bruyette & Woods analyst Alex Bond initiated coverage on Coinshares PLC (NASDAQ:CSHR) with an Outperform rating and announces Price Target of $9. CoinShares shares closed at $6.11 on Tuesday. See how other analysts view this stock. BTIG analyst Thomas Shrader initiated coverage on BIOAGE L
AMD, Under Armour downgraded: Wall Street's top analyst calls
AMD, Under Armour downgraded: Wall Street's top analyst calls